CureVac NV (LTS:0A9E) Beginning Cash Position : $224.8 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is CureVac NV Beginning Cash Position?

CureVac NV's Beginning Cash Position for the quarter that ended in Sep. 2024 was $224.8 Mil.

CureVac NV's quarterly Beginning Cash Position declined from Mar. 2024 ($437.4 Mil) to Jun. 2024 ($323.1 Mil) and declined from Jun. 2024 ($323.1 Mil) to Sep. 2024 ($224.8 Mil).

CureVac NV's annual Beginning Cash Position declined from Dec. 2021 ($1,494.5 Mil) to Dec. 2022 ($859.6 Mil) and declined from Dec. 2022 ($859.6 Mil) to Dec. 2023 ($540.7 Mil).

CureVac NV Beginning Cash Position Historical Data

The historical data trend for CureVac NV's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Beginning Cash Position Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

23.76

37.33

1,494.46

859.60

540.67

CureVac NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beginning Cash Position	Get a 7-Day Free Trial															574.09	506.16	437.45	323.09	224.77

CureVac NV Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

CureVac NV Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of CureVac NV's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (LTS:0A9E) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

CVAC:USA 1CVAC:Italy 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

CureVac NV Headlines

No Headlines